PURPOSE: To investigate the association of overall and disease-specific survival with the five standard treatment modalities for prostate cancer (CaP): radical prostatectomy (RP), brachytherapy (BT), external beam radiotherapy, androgen deprivation therapy, and no treatment (NT) within 6 months after CaP diagnosis. METHODS AND MATERIALS: The study population included 10,179 men aged 65 years and older with incident CaP diagnosed between 1999 and 2001. Using the linked Ohio Cancer Incidence Surveillance System, Medicare, and death certificate files, overall and disease-specific survival through 2005 among the five clinically accepted therapies were analyzed. RESULTS: Disease-specific survival rates were 92.3% and 23.9% for patients with localized vs. distant disease at 7 years, respectively. Controlling for age, race, comorbidities, stage, and Gleason score, results from the Cox multiple regression models indicated that the risk of CaP-specific death was significantly reduced in patients receiving RP or BT, compared with NT. For localized disease, compared with NT, in the monotherapy cohort, RP and BT were associated with reduced hazard ratios (HR) of 0.25 and 0.45 (95% confidence intervals 0.13-0.48 and 0.23-0.87, respectively), whereas in the combination therapy cohort, HR were 0.40 (0.17-0.94) and 0.46 (0.27-0.80), respectively. CONCLUSIONS: The present population-based study indicates that RP and BT are associated with improved survival outcomes. Further studies are warranted to improve clinical determinates in the selection of appropriate management of CaP and to improve predictive modeling for which patient subsets may benefit most from definitive therapy vs. conservative management and/or observation.
PURPOSE: To investigate the association of overall and disease-specific survival with the five standard treatment modalities for prostate cancer (CaP): radical prostatectomy (RP), brachytherapy (BT), external beam radiotherapy, androgen deprivation therapy, and no treatment (NT) within 6 months after CaP diagnosis. METHODS AND MATERIALS: The study population included 10,179 men aged 65 years and older with incident CaP diagnosed between 1999 and 2001. Using the linked Ohio Cancer Incidence Surveillance System, Medicare, and death certificate files, overall and disease-specific survival through 2005 among the five clinically accepted therapies were analyzed. RESULTS: Disease-specific survival rates were 92.3% and 23.9% for patients with localized vs. distant disease at 7 years, respectively. Controlling for age, race, comorbidities, stage, and Gleason score, results from the Cox multiple regression models indicated that the risk of CaP-specific death was significantly reduced in patients receiving RP or BT, compared with NT. For localized disease, compared with NT, in the monotherapy cohort, RP and BT were associated with reduced hazard ratios (HR) of 0.25 and 0.45 (95% confidence intervals 0.13-0.48 and 0.23-0.87, respectively), whereas in the combination therapy cohort, HR were 0.40 (0.17-0.94) and 0.46 (0.27-0.80), respectively. CONCLUSIONS: The present population-based study indicates that RP and BT are associated with improved survival outcomes. Further studies are warranted to improve clinical determinates in the selection of appropriate management of CaP and to improve predictive modeling for which patient subsets may benefit most from definitive therapy vs. conservative management and/or observation.
Authors: Gregory S Merrick; Wayne M Butler; Robert W Galbreath; Jonathan H Lief; Edward Adamovich Journal: Int J Radiat Oncol Biol Phys Date: 2002-03-01 Impact factor: 7.038
Authors: Lars Holmberg; Anna Bill-Axelson; Fred Helgesen; Jaakko O Salo; Per Folmerz; Michael Häggman; Swen-Olof Andersson; Anders Spångberg; Christer Busch; Steg Nordling; Juni Palmgren; Hans-Olov Adami; Jan-Erik Johansson; Bo Johan Norlén Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: Gunnar Steineck; Fred Helgesen; Jan Adolfsson; Paul W Dickman; Jan-Erik Johansson; Bo Johan Norlén; Lars Holmberg Journal: N Engl J Med Date: 2002-09-12 Impact factor: 91.245
Authors: R J Ellis; E H Zhou; P Fu; D A Kaminsky; D B Sodee; P F Faulhaber; D Bodner; M I Resnick Journal: J Urol Date: 2008-03-17 Impact factor: 7.450
Authors: John E Sylvester; John C Blasko; Peter D Grimm; Robert Meier; Judith A Malmgren Journal: Int J Radiat Oncol Biol Phys Date: 2003-11-15 Impact factor: 7.038
Authors: Louis Potters; Eric A Klein; Michael W Kattan; Chandana A Reddy; Jay P Ciezki; Alwyn M Reuther; Patrick A Kupelian Journal: Radiother Oncol Date: 2004-04 Impact factor: 6.280
Authors: George Rodrigues; Xiaomei Yao; D Andrew Loblaw; Michael Brundage; Joseph L Chin Journal: Can Urol Assoc J Date: 2013 May-Jun Impact factor: 1.862
Authors: G L Lu-Yao; S Kim; D F Moore; W Shih; Y Lin; R S DiPaola; S Shen; A Zietman; S-L Yao Journal: Prostate Cancer Prostatic Dis Date: 2015-06-23 Impact factor: 5.554